Myeloma Paper of the Day, June 7th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Response rate and EFS to 2nd line daratumumab/bortezomib/dexamethasone in relapsed/refractory light chain AL amyloidosis after initial bortezomib-based regime are better if prior response was CR/VGPR and if relapsed disease vs. inadequate prior response.”
Source: Robert Orlowski/X
Authors: Joshua Bomsztyk, Sriram Ravichandran, Jahanzaib Khwaja, Oliver Cohen, Muhammad Rauf, Darren Foard, Ana Martinez-Naharro, Lucia Venneri, Carol Whelan, Marianna Fontana, Philip Hawkins, Julian Gillmore, Helen Lachmann, Shameem Mahmood, and Ashutosh Wechalekar.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
